Side effects across medicines
Medicines whose labels list visual impairment
78 medicines have an FDA label that names visual impairment in its boxed warning, warnings, adverse reactions, trial table, patient leaflet or Drug Facts “stop use” warning (of the labels PlainMeds reads: each medicine's quoted label and up to eight more, by route and wording). Among them, the most FAERS reports of visual impairment name methylprednisolone (1,118), sertraline (871) and morphine (797), through July 30, 2026. A label lists what its studies and reports found, and a report does not show that a medicine caused the event.
Check it at the source: the FDA FAERS public dashboard; FDA labels on DailyMed.
Which medicines' labels list visual impairment?
Ordered by where the label names it, the boxed warning first, then by FAERS reports. A medicine whose own indications name it, because it treats it, is not counted.
| Medicine | Where a label names it | FAERS reports of visual impairment |
|---|---|---|
| Belantamab mafodotin | boxed warning | 126 |
| Linezolid | warnings and precautions (oral label) | 188 |
| Amiodarone | warnings and precautions (intravenous label) | 159 |
| Avelumab | warnings and precautions | none in the top 1,000 |
| Avutometinib and defactinib | warnings and precautions | none in the top 1,000 |
| Cosibelimab | warnings and precautions | none in the top 1,000 |
| Retifanlimab | warnings and precautions | none in the top 1,000 |
| Methylprednisolone | adverse reactions (intra-articular/ | 1,118 |
| Sertraline | adverse reactions | 871 |
| Morphine | adverse reactions | 797 |
| Hydromorphone | adverse reactions | 627 |
| Botulinum toxin type a | adverse reactions | 572 |
| Brolucizumab | adverse reactions | 569 |
| Duloxetine | adverse reactions | 551 |
| Voriconazole | adverse reactions | 491 |
| Crizotinib | adverse reactions | 403 |
| Varenicline | adverse reactions | 367 |
| Cyclophosphamide | adverse reactions | 326 |
| Torsemide | adverse reactions | 215 |
| Encorafenib | adverse reactions | 196 |
| Binimetinib | adverse reactions | 180 |
| Hydrochlorothiazide and valsartan | adverse reactions | 148 |
| Amlodipine and hydrochlorothiazide and valsartan | adverse reactions | 114 |
| Tamsulosin | adverse reactions | 113 |
| Ivabradine | adverse reactions | 105 |
| Scopolamine | adverse reactions | 84 |
| Lorlatinib | adverse reactions | 71 |
| Ganciclovir | adverse reactions | 67 |
| Selinexor | adverse reactions | 61 |
| Cobimetinib | adverse reactions | 55 |
| Mirvetuximab soravtansine | adverse reactions | 53 |
| Tranexamic acid | adverse reactions | 49 |
| Alectinib | adverse reactions | none in the top 1,000 |
| Almotriptan | adverse reactions | none in the top 1,000 |
| Amivantamab | adverse reactions | none in the top 1,000 |
| Amlodipine and benazepril | adverse reactions | none in the top 1,000 |
| Auranofin | adverse reactions | none in the top 1,000 |
| Avacincaptad | adverse reactions | none in the top 1,000 |
| Avanafil | adverse reactions | none in the top 1,000 |
| Belzutifan | adverse reactions | none in the top 1,000 |
| Brigatinib | adverse reactions | none in the top 1,000 |
| Brimonidine and carbachol | adverse reactions | none in the top 1,000 |
| Bromocriptine | adverse reactions | none in the top 1,000 |
| Camizestrant | adverse reactions | none in the top 1,000 |
| Carbachol | adverse reactions | none in the top 1,000 |
| Cemiplimab | adverse reactions | none in the top 1,000 |
| Cytarabine and daunorubicin | adverse reactions | none in the top 1,000 |
| Dasatinib | adverse reactions | none in the top 1,000 |
| Datopotamab deruxtecan | adverse reactions | none in the top 1,000 |
| Denileukin diftitox | adverse reactions | none in the top 1,000 |
| Dexmedetomidine | adverse reactions | none in the top 1,000 |
| Dexmethylphenidate and serdexmethylphenidate | adverse reactions | none in the top 1,000 |
| Dutasteride and tamsulosin | adverse reactions | none in the top 1,000 |
| Entrectinib | adverse reactions | none in the top 1,000 |
| Esketamine | adverse reactions | none in the top 1,000 |
| Eslicarbazepine | adverse reactions | none in the top 1,000 |
| Ethinyl estradiol and ferrous fumarate and norethindrone | adverse reactions | none in the top 1,000 |
| Ethinyl estradiol and norgestimate | adverse reactions | none in the top 1,000 |
| Fosfomycin | adverse reactions (intravenous label) | none in the top 1,000 |
| Ifosfamide | adverse reactions | none in the top 1,000 |
| Iodixanol | adverse reactions | none in the top 1,000 |
| Iohexol | adverse reactions | none in the top 1,000 |
| Lasmiditan | adverse reactions | none in the top 1,000 |
| Lopinavir and ritonavir | adverse reactions | none in the top 1,000 |
| Moxidectin | adverse reactions | none in the top 1,000 |
| Naxitamab | adverse reactions | none in the top 1,000 |
| Omidenepag isopropyl | adverse reactions | none in the top 1,000 |
| Pilocarpine | adverse reactions (ophthalmic label) | none in the top 1,000 |
| Poractant alfa | adverse reactions | none in the top 1,000 |
| Pretomanid | adverse reactions | none in the top 1,000 |
| Repotrectinib | adverse reactions | none in the top 1,000 |
| Riboflavin 5-phosphate ophthalmic | adverse reactions | none in the top 1,000 |
| Selumetinib | adverse reactions | none in the top 1,000 |
| Tafenoquine | adverse reactions | none in the top 1,000 |
| Tedizolid | adverse reactions | none in the top 1,000 |
| Telisotuzumab vedotin | adverse reactions | none in the top 1,000 |
| Trastuzumab deruxtecan | adverse reactions | none in the top 1,000 |
| Triptorelin | adverse reactions | none in the top 1,000 |
Source: FDA drug labels via openFDA, read October 8, 2026; FAERS via openFDA, reports through July 30, 2026
Which of them have the most visual impairment reports in FAERS?
Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; MedDRA preferred term “Visual Impairment”
What next?
- Side effects across medicines
- every reaction on PlainMeds
- Report a side effect to the FDA
- MedWatch